S&T Bank Clovis Oncology, Inc. Transaction History

S&T Bank

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.05 - $1.3 $1,000 - $26,000	20,000 Added 50.0%	60,000 $3,000
Q2 2022 Aug 10, 2022	BUY	$0.63 - $2.96 $12,600 - $59,200	20,000 Added 100.0%	40,000 $72,000
Q4 2020 Feb 17, 2021	BUY	$4.13 - $6.41 $41,300 - $64,100	10,000 Added 100.0%	20,000 $96,000
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $56,900 - $96,900	-10,000 Reduced 50.0%	10,000 $68,000
Q1 2020 May 14, 2020	BUY	$3.77 - $11.0 $37,700 - $110,000	10,000 Added 100.0%	20,000 $127,000
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $39,300 - $153,500	10,000 New	10,000 $39,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of S&T Bank, based on Form 13F filings with the SEC.

Stay updated on S&T Bank with notifications on news.